Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tacrolimus - Astellas Pharma

Drug Profile

Tacrolimus - Astellas Pharma

Alternative Names: Advagraf; Astagraf XL; FK 506; FK506E; FK506MR; FR 900506; Fujimycin; Graceptor; L 679934; Modified release tacrolimus; Modigraf; MR tacrolimus; MR4; Prograf; PrografXL; Protopic; Protopy; RTU-007; Tacrolimus extended release capsules; Tacrolimus granules; Tacrolimus hydrate; Talymus; Tsukubaenolide

Latest Information Update: 28 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; LEO Pharma; Mallinckrodt plc; Roche; Senju Pharmaceutical
  • Class Antipsoriatics; Lactones; Macrolides; Skin disorder therapies
  • Mechanism of Action Calcineurin inhibitors; Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Allergic conjunctivitis; Myasthenia gravis; Interstitial lung diseases
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Atopic dermatitis; Coronary artery restenosis; Graft-versus-host disease; Interstitial lung diseases; Intestinal transplant rejection; Lupus nephritis; Myasthenia gravis; Rheumatoid arthritis; Transplant rejection; Ulcerative colitis
  • Phase II Open-angle glaucoma
  • Suspended Dry eyes
  • No development reported Eye disorders; Psoriasis

Most Recent Events

  • 28 Jan 2019 No recent reports of development identified for phase-I development in Psoriasis(In adolescents) in Latvia (Topical, Cream)
  • 28 Jan 2019 No recent reports of development identified for phase-I development in Psoriasis(In adolescents) in USA (Topical, Cream)
  • 28 Jan 2019 No recent reports of development identified for preclinical development in Eye-disorders in Japan (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top